PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 20, 1997New England Journal of Medicine1,217 citations

A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure

View Full Paper
DCDenise M. CardoDCDavid H. CulverCCCarol A. Ciesielski

Key Points

Key points are not available for this paper at this time.

Abstract

BACKGROUND: The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. METHODS: We conducted a case-control study of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. RESULTS: Logistic-regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio= 15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio= 6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio=0.19; 95 percent confidence interval, 0.06 to 0.52). CONCLUSIONS: The risk of HIV infection after percutaneous exposure increases with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cardo et al. (1997) studied this question.

synapsesocial.com/papers/6a70a6b035aa2c282ce1f9ebhttps://doi.org/10.1056/nejm199711203372101
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maternal mortality surveillance, United States, 1980-1985.1988 · 513 citations
  2. 2Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons1989 · 1,078 citations
  3. 3Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA1996 · 487 citations
  4. 4Surveillance of HIV Infection and Zidovudine Use among Health Care Workers after Occupational Exposure to HIV-Infected Blood1993 · 350 citations
  5. 5The Impact of the Syncytium-Inducing Phenotype of Human Immunodeficiency Virus on Disease Progression1994 · 404 citations